- Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion.
- The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall.
- Adjusted EPS decreased 34% to $0.33, as higher sales volumes, increased pricing, and procurement actions were more than offset by cost headwinds and unfavorable foreign exchange rate movements.
- Currency-neutral EPS was $0.37, including a $0.02 per share negative impact from the war in Ukraine.
- Guidance: Perrigo expects FY22 sales growth of 8.5% - 9.5% compared to the previous outlook of 3.5% to 4.5%.
- It sees sales of $4.49 billion - $4.53 billion, beating the consensus of $4.49 billion.
- It expects organic sales growth of 8% - 9% up from 7.0% - 8.0% expected earlier.
- The company expects adjusted EPS of $2.30-$2.40, up from $2.10 - $2.30, reflecting approximately $0.35 from the HRA acquisition, offset by $0.10 from the unfavorable exchange rate, $0.05 Russia impact, and around $0.05 in higher interest expense.
- Price Action: PRGO shares are up 5.52% at $34.11 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in